Article
Oncology
Sebastian Horner, Moustafa Moustafa-Oglou, Karin Teppert, Ilona Hagelstein, Joseph Kauer, Martin Pfluegler, Kristina Neumann, Hans-Georg Rammensee, Thomas Metz, Andreas Herrmann, Helmut R. Salih, Gundram Jung, Latifa Zekri
Summary: This article presents a novel approach to selectively induce apoptosis in lymphoma cells and autoreactive B cells using bispecific antibodies. The developed IgG-based bispecific antibodies show efficient depletion of malignant and autoreactive B cells in vitro and in vivo.
Article
Medicine, Research & Experimental
Alexandra Dreyzin, Sandhya R. Panch, Haneen Shalabi, Bonnie Yates, Steven L. Highfill, Ping Jin, David Stroncek, Nirali N. Shah
Summary: A retrospective study compared the clinical outcomes of patients receiving cryopreserved and fresh CAR T cells for B cell leukemia treatment, showing no differences in expansion, toxicity, and disease response. The findings support the use of cryopreservation in advancing cell therapy.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
(2023)
Article
Biochemistry & Molecular Biology
Sabine Tacke, Rittika Chunder, Verena Schropp, Eduard Urich, Stefanie Kuerten
Summary: This study investigated the effects of a novel class of anti-CD20 monoclonal antibodies on B cells in an animal model of multiple sclerosis. The results showed that these antibodies can modulate the immune response and pathology of the central nervous system driven by B cells, with type II antibodies potentially being more effective in depleting tissue-infiltrating B cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Huei-Jen Chen, Yi-An Cheng, Yu-Tung Chen, Chia-Ching Li, Bo-Cheng Huang, Shih-Ting Hong, I. -Ju Chen, Kai-Wen Ho, Chiao-Yun Chen, Fang-Ming Chen, Jaw-Yuan Wang, Steve R. Roffler, Tian-Lu Cheng, Dung-Ho Wu
Summary: Modification of PLD with CD20-specific mPEG x CD20 enhances the internalization and anti-cancer efficacy of PEG-NPs, improving therapeutic efficacy.
CANCER NANOTECHNOLOGY
(2023)
Article
Multidisciplinary Sciences
Chengxin Luo, Guixian Wu, Xiangtao Huang, Yanni Ma, Yali Zhang, Qiuyue Song, Mingling Xie, Yanni Sun, Yarui Huang, Zhen Huang, Yu Hou, Shuangnian Xu, Jieping Chen, Xi Li
Summary: In comparing new anti-CD20 monoclonal antibodies with rituximab in the induction therapy of CD20(+) B-NHL, it was found that obinutuzumab significantly improved PFS but had higher incidence of adverse events, ofatumumab decreased ORR, and Y-90-ibritumomab tiuxetan increased ORR.
SCIENTIFIC REPORTS
(2021)
Article
Biotechnology & Applied Microbiology
Kai-Wen Ho, I-J U. Chen, Yi-An Cheng, Tzu-Yi Liao, En-Shuo Liu, Huei-Jen Chen, Yun-Chi Lu, Yu-Cheng Su, Steve R. Roffler, Bo-Cheng Huang, Hui-Ju Liu, Ming-Yii Huang, Chiao-Yun Chen, Tian-Lu Cheng
Summary: In this study, a humanized bispecific antibody (BsAbs: CD20 Ab-mPEG scFv) was developed to target liquid tumors, enhancing therapeutic efficacy by improving cancer cellular internalization. The combination of CD20 Ab-mPEG scFv and PEGylated liposomal doxorubicin led to a ninefold increase in tumor cytotoxicity compared to other antibodies in vitro. These results demonstrate the potential of this double-attack strategy in improving therapeutic efficacy for liquid tumors.
JOURNAL OF NANOBIOTECHNOLOGY
(2021)
Article
Oncology
Anne W. J. Martens, Joanne M. Rietveld, Renate de Boer, Fleur S. Peters, An Ngo, Lotte W. H. G. van Mil, Koen de Heer, Marcel Spaargaren, Christie P. M. Verkleij, Niels W. C. J. van de Donk, Homer C. Adams, Eric Eldering, Carel J. M. van Noesel, Raluca Verona, Arnon P. Kater
Summary: T-cell redirecting bispecific antibody teclistamab holds high potential for the treatment of B-cell malignancies, including multiple myeloma, B-cell lymphomas, and chronic lymphocytic leukemia. The study shows that teclistamab can effectively target BCMA-expressing tumor cells and induce T-cell activation, proliferation, and cytotoxicity, regardless of the level of BCMA expression. However, the efficacy of teclistamab is generally lower in mature B-cell malignancies compared to multiple myeloma.
CANCER RESEARCH COMMUNICATIONS
(2022)